The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
A new class of imidazoquinolines, including imiquimod, S-27609 and S-28463, has shown potent immunomodulating, antiviral and antitumor activities in animal models. Imiquimod is currently in phase III clinical trials for treating genital warts. These drugs were evaluated for immunomodulating activities in human PBMC, keratinocyte and fibroblast cultures and after topical application to mice. All...
Recently a new class of immunomodulating agents represented by the molecules imiquimod and R-842 has shown potent antiviral and antitumor activities in animal models. In this study another representative of this class, S-28463 (4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol) was evaluated for its antiviral and immunomodulating activities. S-28463 showed potent antiviral...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.